Mink therapeutics to host r&d event november 10, 2022

New york, oct. 05, 2022 (globe newswire) -- mink therapeutics, inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer t (inkt) cell therapies to treat cancer and other immune-mediated diseases, announced the company will host an in-person and virtual research & development day on thursday, november 10th, 2022 from 4:00-6:00 pm et in boston, ma, and via webcast.
INKT Ratings Summary
INKT Quant Ranking